CRVO CERVOMED INC

CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025

CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025

BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver Developing Topics (late-breaking) virtual and in-person poster presentations at Alzheimer’s Association® International Congress (AAIC) 2025, being held on July 27 – 31, 2025 in Toronto, Canada. The Company will be presenting the results, including new results, from the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB).

Details of the AAIC Developing Topics presentations are as follow:

Poster Title: Effects of neflamapimod (p38α kinase inhibitor) on clinical progression in patients with dementia with Lewy bodies (DLB) without Alzheimer’s disease (AD) Co-Pathology

Format: In-person Poster

Session Name: Developing Topics: Drug Development

Poster Number: #108769

Date and Time: Sunday, July 27, 2025 from 7:30 AM – 4:15 PM EDT



Poster Title: Impact of AD Co-Pathology on Response to Neflamapimod (p38α Kinase Inhibitor) in Patients with Dementia with Lewy Bodies

Format: Virtual Presentation

Session Name: Developing Topics

Poster Number: #108885

The posters will be accessible in the Investor section of the CervoMed website following the presentation.

About CervoMed

CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.

Investor Contact:

PJ Kelleher

LifeSci Advisors



617-430-7579



EN
08/07/2025

Underlying

CRVOCERVOMED INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CERVOMED INC

 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase S...

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at Week 32 of treatment (p=0.0037). This risk reduction improved to 64% (p=0.0001) among patients who have minimal evidence of AD co-pathology ...

July 28, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 202...

CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025 Company to share primary endpoint results at 32-Weeks from Extension phase following late-breaking presentations at Alzheimer's Association International Conference® (AAIC) 2025 Conference call and webcast to be held Monday, July 28 at 8:00 AM ET BOSTON, July 24, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company will host a conference call...

July 24, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Announces Late-Breaking Presentations at Alzheimer’s Associat...

CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025 BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver Developing Topics (late-breaking) virtual and in-person poster presentations at Alzheimer’s Association® International Congress (AAIC) 2025, being held on July 27 – 31, 2025 in Toronto, Canada. The Company will be presenting the results, including new results, from the RewinD-LB Phase 2b stu...

July 8, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Announces New Hire to Support Neflamapimod Development and Co...

CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization Strengthening CMC leadership to prepare for scaled up neflamapimod manufacturing On track to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities BOSTON, June 10, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today reported a key senior leadership hire to oversee the Company’s Chemistry, Manufacturing, and Controls (CMC) di...

June 10, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Reports First Quarter 2025 Financial Results and Provides Cor...

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB) Plan to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities Initiating separate Phase 2a trials to evaluate neflamapimod in patients with primary progressive aphasia and patients in the recovery phase after ischemic stroke BOSTON, May 12, 2025 (GLOBE NEW...

May 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch